Pulmokine
Pulmokine is a privately held biopharmaceutical company founded in 2007 and based in Rensselaer, NY. It appears to develop kinase-based therapeutics for pulmonary and respiratory diseases, operated by founder-CEO Larry Zisman.
- Company typePrivate
- Founded2007
- HeadquartersRensselaer, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pulmokine does
Pulmokine is a privately held biopharmaceutical company founded in 2007 and headquartered in Rensselaer, New York. The company name implies a focus on kinase-based therapeutics targeting pulmonary and respiratory diseases, though no specific drug candidates, pipeline programs, or product portfolio are publicly disclosed. The company operates with a small team of 11-50 employees under founder and CEO Larry Zisman, and has no commercial products listed on its website. Its public-facing web presence is minimal, consisting of a tagline ("Breathe Easy with Pulmokine") and a contact/email signup form protected by Google's reCAPTCHA, with a 2025 copyright notice indicating ongoing operations.
The company's only documented capital event is a $1,000,000 funding round on 2015-03-03 from Broadview Ventures, a venture philanthropy firm with a focus on cardiovascular and pulmonary health. No subsequent funding rounds, partnerships, licensing deals, or M&A activity are recorded in the available data. There is no disclosed revenue, pricing model, or distribution channel; the business model appears to be early-stage R&D dependent on grant funding, angel/venture philanthropy capital, or potential future licensing of kinase inhibitor assets. The company has no documented certifications, regulatory filings, patents, trademarks, or named customers, and no social media or app ecosystem is present.
Given the absence of pipeline disclosures, product launches, or commercial milestones, Pulmokine appears to be operating as a niche, research-stage biopharmaceutical entity where the underlying value proposition—likely a proprietary kinase inhibitor program targeting pulmonary indications—remains largely internal. The single source of public information is the company's own website, which indicates the company is still operating but provides no substantive evidence of clinical progression, regulatory milestones, or scale.
Pulmokine firmographics
Firmographics- Name
- Pulmokine
- Legal name
- Pulmokine
- Website
- https://pulmokine.net
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pulmokine is a privately held biopharmaceutical company founded in 2007 and based in Rensselaer, NY. It appears to develop kinase-based therapeutics for pulmonary and respiratory diseases, operated by founder-CEO Larry Zisman.
- Ownership category
- akta.pro rank
Pulmokine industry classification
Industry- Product category
- Pulmonary Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
- akta.pro secondary industries
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)
Keywords
Where Pulmokine is headquartered
LocationHeadquarters
- HQ city
- Rensselaer
- HQ country
- United States
- HQ region
- North America
Markets served
Pulmokine business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
Pulmokine product offering
Product offeringCore offering
Pulmokine is a privately held biopharmaceutical company whose name ("pulmonary" + "kinase") indicates a focus on developing kinase-targeted therapeutics for pulmonary/respiratory diseases. The publicly available website does not list any specific products, drug candidates, or pipeline assets, and currently shows only a contact form and email signup form under the tagline "Breathe Easy with Pulmokine." [Inferred: kinase-based pulmonary therapeutics based on company name]
Product overview
Pulmokine appears to be a pharmaceutical/biotechnology company focused on pulmonary/respiratory health based on its company name (combining 'pulmonary' and 'kinase'). However, the source website provides no specific product listings, named offerings, or detailed service descriptions. The minimal landing page consists only of a contact form and email signup functionality, with no product portfolio, features, or service details available for extraction.
Differentiator
Problem solved
Functional benefit
Companies that use Pulmokine
Customer profileIdeal customer profiles1 record
Pulmokine technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Pulmokine partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Pulmokine competitors and assessment
Company assessmentDirect peers
- Galapagos NV: European biotech historically focused on kinase and inflammation targets with pulmonary fibrosis programs (e.g., ziritaxestat). Comparable as a kinase-focused developer in pulmonary disease; also illustrates the late-stage clinical risk in this space.
- Pliant Therapeutics: Clinical-stage biotech developing integrin-targeted therapies for fibrotic lung diseases (e.g., IPF). Comparable as a small, mechanism-focused pulmonary biotech pursuing novel biological targets in respiratory indications.
- Verona Pharma: Late-stage respiratory biopharma developing ensifentrine, a first-in-class dual PDE3/PDE4 inhibitor for COPD. Comparable as a focused, small-cap pulmonary therapeutics developer advancing differentiated mechanisms in major respiratory indications.
Emerging players
- FibroGen: Biotech developing therapies for fibrotic and respiratory diseases including IPF (pamrevlumab). Comparable as a focused developer in pulmonary fibrosis with kinase/biological pathway programs in similar indications.
- Sciwind Biosciences: China-based biopharma developing inhaled biologics for metabolic and respiratory diseases. Comparable as a small, mechanism-focused respiratory therapeutic developer addressing similar pulmonary indications.
- Respivant Sciences: Earlier-stage pulmonary biotech focused on inhaled therapies for rare respiratory diseases. Comparable as a small, indication-focused respiratory therapeutic developer.
Broad incumbents
- United Therapeutics: Established pulmonary hypertension and rare lung disease company with multiple approved products (e.g., Tyvaso, Remodulin). Comparable in therapeutic area focus (pulmonary vascular/respiratory) but operates at commercial scale with diversified pipeline.
- Insmed: Specialty biopharma focused on serious pulmonary and rare diseases (e.g., ARIKAYCE for MAC lung disease). Comparable to Pulmokine as a focused respiratory therapeutic developer, but with commercial-stage assets and substantially greater capitalization.
- AstraZeneca (Respiratory & Immunology): Major respiratory and immunology franchise with severe asthma, COPD, and rare disease programs (e.g., Fasenra, Trixeo). Comparable as a respiratory therapeutic leader and likely strategic acquirer of differentiated early-stage pulmonary assets.
- Boehringer Ingelheim (Respiratory): Large pharmaceutical company with a leading respiratory franchise (e.g., Spiriva, Ofev/nintedanib, a kinase inhibitor approved for IPF). Comparable as a kinase-inhibitor developer in pulmonary disease, representing both a competitive threat and a potential acquirer/partner for Pulmokine.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks2 records
Key highlights4 records
Customer concentration
Pulmokine social profiles
Digital presencePulmokine financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pulmokine leadership team
Management profileNumber of profiles
Profiles1 record
Pulmokine funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pulmokine M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pulmokine
What does Pulmokine do?
Pulmokine is a privately held biopharmaceutical company whose name ("pulmonary" + "kinase") indicates a focus on developing kinase-targeted therapeutics for pulmonary/respiratory diseases. The publicly available website does not list any specific products, drug candidates, or pipeline assets, and currently shows only a contact form and email signup form under the tagline "Breathe Easy with Pulmokine." [Inferred: kinase-based pulmonary therapeutics based on company name]
Is Pulmokine a public or private company?
Pulmokine is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pulmokine founded?
Pulmokine was founded in 2007. It employs 11 to 50 people.
Where is Pulmokine based?
Pulmokine is headquartered in Rensselaer, United States, in the North America region.
Who are Pulmokine's main competitors?
Direct peers on record are Galapagos NV, Pliant Therapeutics and Verona Pharma. Emerging players are FibroGen, Sciwind Biosciences and Respivant Sciences. Broad incumbents are United Therapeutics, Insmed, AstraZeneca (Respiratory & Immunology) and Boehringer Ingelheim (Respiratory).
Does Pulmokine have an API?
No public API is recorded for Pulmokine.
What industry is Pulmokine in?
Pulmokine's product category is Pulmonary Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.